Genesis Bioventures announces international scientist joins Scientific Advisory Board

Mar 07, 2006, 00:00 ET from Genesis Bioventures, Inc.

    NEW YORK, March 7 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc.
 (GBI) - (OTCBB:GBIW) and its business advisor, Experigen Management Company
 (Experigen) announced today that Lou Lome has joined GBI as a Scientific
     Mr. Lome is noted for his scientific contributions spanning three decades
 of service to the United States government at the highest levels of science at
 the Office of Research and Development at the Central Intelligence Agency, the
 Innovative Science & Technology Office of the Strategic Defense Initiative
 Organization, the Department of Defense Science and Technology Program in
 Electronic Warfare, and most recently as a research scientist for the
 Institute for Defense Analysis (IDA). Mr. Lome's experience includes
 technology innovation in communications and information technology, VLSI,
 image and signal processing programs, advanced information surveillance,
 quantum computing, and nanotechnology.
     "We are very pleased Mr. Lome has joined GBI's advisory team," said Greg
 McCartney, President of GBI. "His outstanding science background, his
 extensive network of world leading scientists and his in-depth experience in
 large scale project management becomes very important to our success as we
 continue to build GBI and manage our current investment companies to
     "We are very serious about increasing GBI's commercial and scientific
 focus," said Douglas C. Lane of Experigen. "Mr. Lome's experience in advanced
 satellite surveillance systems and RFID devices will help us exploit a new and
 potentially exciting channel to our Prion Developmental Laboratory company's
 opportunities: animal tracking and record maintenance systems that are
 becoming an increasing mandate of the beef import and export industry by
 foreign and domestic governments. And, with Mr. Lome's participation, we now
 stand to benefit from synergies in oncology and nanotechnology that are being
 developed globally which complement and may increase our Biomedical
 Diagnostic, Inc. company's MSA breast cancer diagnostic technology, and
 possible therapeutic opportunities that may develop as a result."
     Mr. Lome is also an advisor to the International Technology Roadmap for
 Semiconductors (ITRS), Emerging Research Devices (ERD), NASA Jet Propulsion
 Laboratory, Oak Ridge National Laboratory, and the Nanotechnology Science &
 Technology Institute. He is a member of over twenty exclusive science
 professional societies, including senior member of the Institute for
 Electrical and Electronic Engineers (IEEE), life member of the American
 Physical Society (APS), fellow of the Optical Society of America (OSA),
 Society for Photo-optical Interpretation Engineers (SPIE), Society for
 Mathematical Biology (SMB), among others, and he is Chair of numerous
 conferences within IEEE and SPIE, and the Nanotech 2005 Government Forum.
     About Experigen
     Experigen is a management company retained by Genesis Bioventures, Inc.
 to develop and advance GBI's investment portfolio, financing and operations.
     About Genesis Bioventures, Inc.
     Genesis Bioventures, Inc. is a biomedical development corporation
 focusing on the development and marketing of novel diagnostics and
 therapeutics in oncology and neurodegenerative diseases.
     Statements in this press release that are not strictly historical facts
 are "forward looking" statements (identified by the words "believe",
 "estimate", "project", "expect" or similar expressions) within the meaning of
 the Private Securities Litigation Reform Act of 1995. These statements
 inherently involve risks and uncertainties that could cause actual results to
 differ materially from the forward-looking statements. Factors that would
 cause or contribute to such differences include, but are not limited to,
 continued acceptance of the Company's products and services in the
 marketplace, competitive factors, changes in the regulatory environment, and
 other risks detailed in the Company's periodic report filings with the
 Securities and Exchange Commission. The statements in this press release are
 made as of today, based upon information currently known to management, and
 the Company does not undertake any obligation to publicly update or revise any
 forward-looking statements.
     GBI Investor Relations: (604) 542-0820,,
     Experigen: (310) 443-4100,,

SOURCE Genesis Bioventures, Inc.